The pathway for the introduction of NK cell into abnormal cells is mediated by the receptor-ligand interaction on the cell surface. Among all the activation receptors, NKP44 has become a unique activation receptor because it has an ITIMs signaling pathway and actively plays an important role in several functions of stimulated NK cells. A potential ligand that can specifically regulate the activity of NKP44 receptors is NID1. NID1 is a novel ligand that can initiate two different regulations on NK cells activity. In addition, NID1 also provides predictions that are compatible with the electrophoretic glycoprotein mobility that has been detected by NKp44 through SDS-PAGE and ELISA tests compared to all proteins in the microenvironment of ovarian cancer. Curently, NID1 has been proven to be able to increase the cytotoxic reaction of non-cancerous NK cells. Further research is needed for the development of ovarian cancer immunotherapy based on the receptor-ligand interactions.